Abstract:Background: Respiratory syncytial virus (RSV) is the most common cause of viral lower respiratory tract infections (LRTIs) in young children around the world and an important cause of LRTI in the elderly. The available treatments and FDA-approved vaccines for RSV only lessen the severity of the infection and are recommended for infants and elderly people. Methods: We focused on developing a broad-spectrum vaccine that activates the immune system to directly combat RSV. The objective of this study is to identify CD4 + and CD8 + T-cell epitopes using an immunoinformatics approach to develop RSV vaccines. The efficacy of these peptides was validated through in-vitro and in-vivo studies involving healthy and diseased animal models. Results: For each major histocompatibility complex (MHC) class-I and II, we found three epitopes of RSV proteins including F, G, and SH with an antigenic score of >0.5 and a projected SVM score of <5. Experimental validation of these peptides on female BALB/c mice was conducted before and after infection with the RSV A2 line 19f. We found that the 3RVMHCI (CD8 + ) epitope of the F protein showed significant results of white blood cells (19.72 × 10 3 cells/μl), neutrophils (6.01 × 10 3 cells/μl), lymphocytes (12.98 × 10 3 cells/μl), IgG antibodies (36.9 μg/ml), IFN-γ (86.96 ng/L), and granzyme B (691.35 pg/ml) compared to control at the second booster dose of 10 μg. Similarly, 4RVMHCII (CD4 + ) of the F protein substantially induced white blood cells (27.08 × 10 3 cells/μl), neutrophils (6.58 × 10 3 cells/μl), lymphocytes (16.64 × 10 3 cells/μl), IgG antibodies (46.13 μg/ml), IFN-γ (96.45 ng/L), and granzyme B (675.09 pg/ml). In-vitro studies showed that 4RVMHCII produced a significant level of antibodies in sera on day 45 comparable to mice infected with the virus. 4RVMHCII also induced high IFN-γ and IL-2 secretions on the fourth day of the challenge compared to the preinfectional stage. Conclusion: In conclusion, epitopes of the F protein showed considerable immune response and are suitable for further validation.

Vaccine-elicited CD8+ T cells protect against respiratory syncytial virus-induced lung airway obstruction (113.8)

Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice

Pre-existing neutralizing antibodies prevent CD8 T cell-mediated immunopathology following respiratory syncytial virus infection

Experimental trials of predicted CD4+ and CD8+ T-cell epitopes of respiratory syncytial virus

The CD4 T cell response to respiratory syncytial virus infection

Human T cells efficiently control RSV infection

Tissue-Resident Memory T Cells in the Lungs Protect against Acute Respiratory Syncytial Virus Infection

Recombinant live attenuated influenza vaccine viruses carrying CD8 T-cell epitopes of respiratory syncytial virus protect mice against both pathogens without inflammatory disease

The CD8 T Cell Response to Respiratory Virus Infections

RSV Vaccine-Enhanced Disease Is Orchestrated by the Combined Actions of Distinct CD4 T Cell Subsets

A Recombinant G Protein Plus Cyclosporine A–Based Respiratory Syncytial Virus Vaccine Elicits Humoral and Regulatory T Cell Responses against Infection without Vaccine-Enhanced Disease

Additive Protection Induced by Mixed Virus-Like Particles Presenting Respiratory Syncytial Virus Fusion or Attachment Glycoproteins.

Poly(U) and CpG ameliorate the unbalanced T cell immunity and pneumonia of mice with RSV vaccine-enhanced disease

A Safe and Effective Mucosal RSV Vaccine Consisting of RSV Phosphoprotein and Flagellin Variant

RSV recombinant candidate vaccine G1F/M2 with CpG as an adjuvant prevents vaccine-associated lung inflammation, which may be associated with the appropriate types of immune memory in spleens and lungs

Respiratory Syncytial Virus Elicits Enriched CD8+ T Lymphocyte Responses in Lung Compared with Blood in African Green Monkeys.

A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection

Virus-like Nanoparticle and DNA Vaccination Confers Protection Against Respiratory Syncytial Virus by Modulating Innate and Adaptive Immune Cells.

Assessing the protection elicited by virus-like particles expressing the RSV pre-fusion F and tandem repeated G proteins against RSV rA2 line19F infection in mice

Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice

Protection Induced By Virus-Like Particle Vaccine Containing Tandem Repeat Gene Of Respiratory Syncytial Virus G Protein